IP Library › Granted Patent US 12,508,267
Granted Patent B2
US 12,508,267 · App. 17/934,680 · Granted Dec 30, 2025

Isotopically-labelled trapidil derivatives

Inventors: Aarash Bordbar (San Diego, CA); Warren S. Wade (San Diego, CA); Hiroko Masamune (San Diego, CA)
Assignee: SINOPIA BIOSCIENCES, INC.
A61K31/519A61K31/198A61P25/16C07D487/04C07B2200/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,508,267
App. No.
17/934,680
Granted
Dec 30, 2025
Kind
B2
Abstract

Provided are isotopically-labelled Trapidil derivatives useful for the treatment of Parkinson's disease and movement disorders associated with Parkinson's disease. The isotopically-labelled Trapidil derivatives include deuterated Trapidil derivatives. Additionally provided are combination therapies of isotopically-labelled Trapidil derivatives and additional therapeutic agents for the treatment of Parkinson's disease and movement disorders associated with Parkinson's disease.

Claims (12)

1 . A compound or a pharmaceutically-acceptable salt or solvate thereof, wherein the compound is:

2 . The compound of claim 1 or the pharmaceutically-acceptable salt or solvate thereof, wherein the compound is:

3 . The compound of claim 1 or the pharmaceutically-acceptable salt or solvate thereof, wherein the compound is:

4 . The compound of claim 1 or the pharmaceutically-acceptable salt or solvate thereof, wherein positions represented as D of the compound have deuterium enrichment of at least 98%.

5 . The compound of claim 1 or the pharmaceutically-acceptable salt or solvate thereof, wherein positions represented as D of the compound have deuterium enrichment of at least 90%.

6 . A pharmaceutical composition, comprising:

an effective amount of the compound of claim 1 , or the pharmaceutically acceptable salt or solvate thereof; and

a pharmaceutically acceptable; diluent, excipient or carrier.

7 . A method of treating Parkinson's disease or a movement disorder associated with Parkinson's disease in a subject in need thereof, comprising: administering to the subject the compound of claim 1 or the pharmaceutically acceptable salt or solvate thereof.

8 . The method of claim 7 , further comprising administering levodopa to the subject.

9 . The method of claim 7 , wherein the movement disorder is dyskinesia.

10 . The method of claim 7 , wherein the movement disorder is dystonia.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE E-SIGNATURE FROM HIROKO MASAMUNE. HIROKO MASAMUNE HAS RE-SIGNED WITH A WET SIGNATURE. PREVIOUSLY RECORDED ON REEL 62594 FRAME 339. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECTIVE ASSIGNMENT. Recorded Dec 5, 2025
From: BORDBAR, AARASH; WADE, WARREN S.; MASAMUNE, HIROKO
To: SINOPIA BIOSCIENCES, INC.
Reel/Frame 073886/0667 →
CONFIRMATORY LICENSE Recorded Aug 2, 2023
From: SINOPIA BIOSCIENCES INC
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 064476/0095 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2022
From: BORDBAR, AARASH; WADE, WARREN S.; MASAMUNE, HIROKO
To: SINOPIA BIOSCIENCES, INC.
Reel/Frame 062594/0339 →
Continuity (4)
Continuation PCTUS2021024226 · Mar 25, 2021
Provisional Application 63063846 · Aug 10, 2020
Provisional Application 63000347 · Mar 26, 2020
Related Publication 20230102580A1 · Mar 30, 2023
References Cited (149)
US 4327725A · Cortese et al. · 1982 [cited by applicant]
US 4624848A · Lee · 1986 [cited by applicant]
US 4739044A · Stabinsky · 1988 [cited by applicant]
US 4757141A · Fung et al. · 1988 [cited by applicant]
US 4843155A · Chomczynski · 1989 [cited by applicant]
US 4968509A · Radebaugh et al. · 1990 [cited by applicant]
US 5348853A · Wang et al. · 1994 [cited by applicant]
US 5384261A · Winkler et al. · 1995 [cited by applicant]
US 5445934A · Fodor et al. · 1995 [cited by applicant]
US 5456923A · Nakamichi et al. · 1995 [cited by applicant]
US 5461140A · Heller et al. · 1995 [cited by applicant]
US 5516527A · Curatolo · 1996 [cited by applicant]
US 5567583A · Wang et al. · 1996 [cited by applicant]
US 5622721A · Dansereau et al. · 1997 [cited by applicant]
US 5677195A · Winkler et al. · 1997 [cited by applicant]
US 5686105A · Kelm et al. · 1997 [cited by applicant]
US 5700410A · Nakamichi et al. · 1997 [cited by applicant]
US 5708153A · Dower et al. · 1998 [cited by applicant]
US 5738874A · Conte et al. · 1998 [cited by applicant]
US 5744305A · Fodor et al. · 1998 [cited by applicant]
US 5770358A · Dower et al. · 1998 [cited by applicant]
US 5770722A · Lockhart et al. · 1998 [cited by applicant]
US 5789162A · Dower et al. · 1998 [cited by applicant]
US 5800992A · Fodor et al. · 1998 [cited by applicant]
US 5854033A · Lizardi · 1998 [cited by applicant]
US 5858401A · Bhalani et al. · 1999 [cited by applicant]
US 5869717A · Frame et al. · 1999 [cited by applicant]
US 5874219A · Rava et al. · 1999 [cited by applicant]
US 5977175A · Lin · 1999 [cited by applicant]
US 5994056A · Higuchi · 1999 [cited by applicant]
US 6015578A · Walch · 2000 [cited by applicant]
US 6020135A · Levine et al. · 2000 [cited by applicant]
US 6033854A · Kurnit et al. · 2000 [cited by applicant]
US 6033860A · Lockhart et al. · 2000 [cited by applicant]
US 6040138A · Lockhart et al. · 2000 [cited by applicant]
US 6040193A · Winkler et al. · 2000 [cited by applicant]
US 6171785B1 · Higuchi · 2001 [cited by applicant]
US 6344316B1 · Lockhart et al. · 2002 [cited by applicant]
US 6369065B1 · Chatelain et al. · 2002 [cited by applicant]
US 6465014B1 · Moroni et al. · 2002 [cited by applicant]
US 6667048B1 · Lambert et al. · 2003 [cited by applicant]
US 6932983B1 · Straub et al. · 2005 [cited by applicant]
US 6960563B2 · Egbaria et al. · 2005 [cited by applicant]
US 10350212B2 · Bordbar · 2019 [cited by examiner]
US 10350312B2 · Zabow et al. · 2019 [cited by applicant]
US 11281170B2 · Jones et al. · 2022 [cited by applicant]
US 11628170B2 · Bordbar · 2023 [cited by examiner]
US 12268691B2 · Bordbar · 2025 [cited by examiner]
US 20060166972A1 · Conn et al. · 2006 [cited by applicant]
US 20070117765A1 · Sauve et al. · 2007 [cited by applicant]
US 20080242657A1 · Marino et al. · 2008 [cited by applicant]
US 20080293713A1 · Liu et al. · 2008 [cited by applicant]
US 20090192111A1 · Bader et al. · 2009 [cited by applicant]
US 20120208706A1 · Downing et al. · 2012 [cited by applicant]
US 20180243307A1 · Bordbar · 2018 [cited by applicant]
US 20190328741A1 · Bordbar · 2019 [cited by applicant]
US 20220378794A1 · Bordbar · 2022 [cited by applicant]
US 20230201205A1 · Bordbar · 2023 [cited by applicant]
CN 101720327A · 2010 [cited by applicant]
EP 0301423A1 · 1989 [cited by applicant]
KR 20150015854A · 2015 [cited by applicant]
WO WO9309781A1 · 1993 [cited by applicant]
WO WO9526325A2 · 1995 [cited by examiner]
WO WO2014019979A1 · 2014 [cited by applicant]
WO WO2017059113A1 · 2017 [cited by applicant]
WO WO2017176652A2 · 2017 [cited by examiner]
WO WO2019149660A1 · 2019 [cited by applicant]
WO WO2021113266A1 · 2021 [cited by applicant]
WO WO2021195425A1 · 2021 [cited by applicant]
WO WO2021262786A1 · 2021 [cited by applicant]
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface. (Year: 2005). [cited by examiner]
Agrawal, et al. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling. Tetrahedron Letters. 1990 31:1543-1546. [cited by applicant]
Allen et al., The structure of certain polyazaindenes. III. 1,2,3a,7- and 1,3,3a,7-tetrazaindenes. The Journal of Organic Chemistry 24(6):793-796 (1959). [cited by applicant]
Bank et al. Substituent effect on the electrochemical oxidation of arylmethyl anions. 3. Effect of methyl substitution on diarylmethyl anions. J Org Chem 48(20):3458-3464 (1983). [cited by applicant]
Barany. Genetic disease detection and DNA amplification using cloned thermostable ligase. PNAS USA 88:189-193 (1991). [cited by applicant]
Bethke et al., Effects of the triazolopyrimidine trapidil on force of contraction, beating frequency and phosphodiesterase I-IV activity in guinea-pig hearts. Arzneimittelforschung 41(5):461-468 (1991). [cited by applicant]
Cao et al. Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements. J Neurosci 30(21):7335-7343 (2010). [cited by applicant]
Caruthers. Gene synthesis machines: DNA chemistry and its uses. Science 230(4723):281-285 (1985). [cited by applicant]
Cenci et al. Ratings of L-DOPA-Induced Dyskinesia in the Unilateral 6-OHDA Lesion Model of Parkinson's Disease in Rats and Mice. Curr Protoc Neurosci Chapter 9:Unit 9.25 (23 pgs) (2007). [cited by applicant]
Deslauriers et al. Implication of the ERK/MAPK pathway in antipsychotics-induced dopamine D2 receptor upregulation and in the preventive effects of (+/−)-alpha-lipoic acid in SH-SY5Y neuroblastoma cells. J Mol Neurosci … [cited by applicant]
Fries et al. Parallel NMR Based on Solution Magnetic-Susceptibility Differences. Application to Isotopic Effects on Self-Diffusion. J Chem Eng Data 55(5):2048-2054 (2010). [cited by applicant]
Giessler et al. Trapidil derivatives as potential antiatherosclerotic drugs. Arzneimittelforschung 37(5):538-41 (1987). [cited by applicant]
Giorgi et al. Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms. Eur J Neurosci. 28(5):941-50 (2008). [cited by applicant]
Giusti et al. Synthesis and characterization of 5′-fluorescent-dye-labeled oligonucleotides. PCR Methods Appl. 2(3):223-227 (1993). [cited by applicant]
Guatelli et al. Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication. PNAS USA 87(5):1874-1878 (1990). [cited by applicant]
Gupta et al. A general method for the synthesis of 3′-sulfhydryl and phosphate group containing oligonucleotides. Nucleic Acids Res. 19(11):3019-3025 (1191). [cited by applicant]
Heid et al. Real time quantitative PCR. Genome Res. 6(10):986-994 (1996). [cited by applicant]
Heiman et al. Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia. PNAS USA 111(12):4578-4583 (2014). [cited by applicant]
Heinroth et al. Influence of Trapidil derivatives on arachidonic acid- and prostaglandin endoperoxide analogue-induced platelet aggregation and thromboxane A2 formation. Biomedica biochimica acta 43(8-9):S389-392 (Abstr… [cited by applicant]
Heinroth-Hoffmann et al. Influence of Trapidil and Trapidil Derivatives on the Content of Cyclic Nucleotides in Human Intima Cells Cultured from Atherosclerotic Plaques. Drug Development Res 19(3):321-327 (1990). [cited by applicant]
Kwoh et al. Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format. PNAS USA 86(4):1173-1177 (1989). [cited by applicant]
Lamb et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease. Science 313:1929-1935 (2006). [cited by applicant]
Liberman et al. Pharmaceutical Dosage Forms. 2nd Ed. 1:209-214 (1990). [cited by applicant]
Lizardi et al. Exponential amplification of recombinant-RNA hybridization probes. Nature Biotechnology 6:1197-1202 (1988). [cited by applicant]
Nakagawa et al. Simultaneous determination of trapidil and its metabolites in serum by high-performance liquid chromatography. Yakugaku Zasshi 104(6):635-639 (1984). [cited by applicant]
Nelson et al. Bifunctional oligonucleotide probes synthesized using a novel CPG support are able to detect single base pair mutations. Nucleic Acids Res. 17(18):7187-7194 (1989). [cited by applicant]
Nguyen et al. Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine. PNAS USA 89(10):4270-4274 (1992). [cited by applicant]
Nogrady. Medicinal Chemistry A Biochemical Approach, Oxford University Press, New York, pp. 388-392 (1985). [cited by applicant]
Osinski et al. Pharmakologische Ansatze einer Proteinkinase A-Aktivierung zur Hemmung der Mitogenese glatter Gefallmuskelzellen. zur Erlangung des Doktorgrades der Mathematisch-Naturwissenschaftlichen Fakultat der Heinr… [cited by applicant]
PCT/US2018/025788 International Search Report and Written Opinion dated Apr. 9, 2018. [cited by applicant]
PCT/US2021/024226 International Invitation to Pay Additional Fees dated May 28, 2021. [cited by applicant]
PCT/US2021/024226 International Search Report and Written Opinion dated Aug. 5, 2021. [cited by applicant]
Pfeifer et al. Biotransformation of the Trapidil (rocornal) derivative AR 12463 in the rat. Die Pharmazie 45(8), 609-614 (1990) (English Abstract). [cited by applicant]
Ploem. Chapter 1: Fluorescence Microscopy. Fluorescent and Luminescent Probes for Biological Activity Mason, T. G. Ed., Academic Press, Landon, pp. 1-11 (1993). [cited by applicant]
Pubmed compound record for CID 169505, 5-Methyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine https://pubchem.ncbi.nlm.nih.gov/compound/169505 (2005). [cited by applicant]
Raubach et al. Double-blind randomized multicenter study on the efficacy of trapidil versus isosorbide dinitrate in stable angina pectoris. Clin Cardiol. 20(5):483-8 (1997). [cited by applicant]
Riedel et al. Efficacy of trapidil and some trapidil derivatives on drug-induced cardiac arrhythmias in rats and guinea pigs. Arzneimittel-Forschung 37.8: 923-926 (1987) (English Abstract). [cited by applicant]
Santini et al. L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J Neurochem 108(3):621-633 (2009). [cited by applicant]
Saulnier et al. An Efficient Method For The Synthesis of Guanidino Prodrugs. Bioorganic and Medicinal Chemistry Letters 4(16):1985-1990 (1994). [cited by applicant]
Sharma et al. Phosphodiesterases: Regulators of cyclic nucleotide signals and novel molecular target for movement disorders. Eur J Pharmacol . 714(1-3):486-97 (2013). [cited by applicant]
Silverman et al. Chapter 8: Prodrugs and drug delivery systems. In: The Organic Chemistry of Drug Design and Drug Action. San Diego: Academic Press, Inc. p. 352-401 (1992). [cited by applicant]
Singh et al. Encyclopedia of Pharmaceutical Technology 2nd Ed. pp. 751-753 (2002). [cited by applicant]
Singh et al. Encyclopedia of Pharmaceutical Technology 2nd Ed., pp. 754-757 (2002). [cited by applicant]
Smith et al. Fluorescence detection in automated DNA sequence analysis, Nature 321:674-679 (1986). [cited by applicant]
Smith et al. Striatal mRNA expression patterns underlying peak dose L-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat. Neuroscience 324:238-251 (2016). [cited by applicant]
Smith et al. The synthesis of oligonucleotides containing an aliphatic amino group at the 5′ terminus: synthesis of fluorescent DNA primers for use in DNA sequence analysis. Nucl. Acid Res. 13:2399-2412 ( 1985). [cited by applicant]
Stahl et al. Supplementary material—list of pharmaceutically acceptable acids. Handbook of Pharmaceutical Salts (1 pg.) (2002). [cited by applicant]
Thanvi et al. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J. 83(980):384-388 (2007). [cited by applicant]
Thiirmann et al. Pharmacokinetics of the PDGF-antagonist Trapidil in patients with and without renal impairment. Clin Nephrol 47(2):99-105 (Abstract only) (1997). [cited by applicant]
U.S. Appl. No. 15/962,999 Office Action dated Jul. 16, 2018. [cited by applicant]
U.S. Appl. No. 15/962,999 Office Action dated Mar. 8, 2019. [cited by applicant]
U.S. Appl. No. 15/962,999 Office Action dated Nov. 6, 2018. [cited by applicant]
U.S. Appl. No. 16/503,128 Office Action dated Jun. 1, 2021. [cited by applicant]
U.S. Appl. No. 16/503,128 Office Action dated Jun. 16, 2022. [cited by applicant]
U.S. Appl. No. 16/503,128 Office Action dated Mar. 30, 2020. [cited by applicant]
U.S. Appl. No. 16/503,128 Office Action dated Nov. 5, 2020. [cited by applicant]
Yershov et al. DNA analysis and diagnostics on oligonucleotide microchips. PNAS USA 93(10):4913-4918 (1996). [cited by applicant]
CAS Registry No.: 100557-05-9, 2-[[5-(Diethylamino)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]pentylamino]ethanol. Retrieved Date:Mar. 21, 2024. [cited by applicant]
Corsini, A, et al., Trapidil derivatives and low density lipoprotein metabolism by human skin fibroblasts and by human hepatoma cell line Hep G2. Pharmacological Research 21(5):521-31 (1989). [cited by applicant]
Nakagawa, H, et al., Simultaneous determination of trapidil and its metabolites in serum by high-performance liquid chromatography. Yakugaku Zasshi 104(6):635-9 (1984) (English Abstract). [cited by applicant]
Osinski, Michael, et al., Pharmacological approaches one Protein kinase A activation to inhibition the mitogenesis of vascular smooth muscle cells. Dissertation Düsseldorf 111 pages (2000). [cited by applicant]
Walsmann, P, et al., Biochemical and pharmacological aspects of the thrombin inhibitor hirudin. Die Pharmazie 36(10):653,653-660 (1981). [cited by applicant]
Jiang, Wenfeng et al., Application of Deuteration in Drug Research. Qilu Pharmaceutical Affairs 29(11):682-683 (2010) (English Abstract). [cited by applicant]
Barnum, C.J. et al. Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta. Neurscience 156(1):30-41 (2008). [cited by applicant]
Bornschein, I. et al. Biotransformation von Trapidil (Roncornal). Pharmazie 33(1):51-63 (1978) (English Abstract). [cited by applicant]
Harder, Sebastian et al. Pharmacokinetics of trapidil, an antagonist of platelet derived growth factor, in healthy subjects and in patients with liver cirrhosis. British journal of clinical pharmacology 42(4):443-449 (1… [cited by applicant]
Harris, et al. Single-molecule DNA sequencing of a viral genome. Science 320(5872): 106-9 (2008). [cited by applicant]
Ip et al. Analysis of complex metabolic behavior through pathway decomposition. BMC Syst Biol 5:91 (2011). [cited by applicant]
Krause et al. Advances in Pharmacological Research and Practice: Proceedings of the 4th Congress of the Hungarian Pharmacological Society, Budapest, pp. 139-142 (1985). [cited by applicant]
Margulies, Marcel et al. Genome Sequencing in Microfabricated High-density Picolitre Reactors. Nature 437(7057):376-380 (2005). [cited by applicant]
Soni, Gautam V. et al. Progress Toward Ultrafast DNA Sequencing Using Solid-state Nanopores. Clinical Chemistry 53(11):1996-2001 (2007). [cited by applicant]
U.S. Appl. No. 15/151,082 Office Action dated Dec. 13, 2018. [cited by applicant]
U.S. Appl. No. 15/151,082 Office Action dated Jun. 14, 2018. [cited by applicant]
U.S. Appl. No. 18/176,962 Office Action dated Aug. 12, 2024. [cited by applicant]
Zuckerman et al. Efficient methods for attachment of thiol specific probes to the 3′-ends of synthetic oligodeoxyribonucleotides. Nucelic Acid Res 15(13):5305-5321 (1987) (in spec as Polynucleotides Res., 15: 5305-5321). [cited by applicant]
Foster, Allan B. Deuterium Isotope Effects In The Metabolism Of Drugs And Xenobiotics: Implications For Drug Design. Advances in Drug Research 14:1-40 (1985). [cited by applicant]
Bezard, Erwan et al. Study of the Antidyskinetic Effect of Eltoprazine in Animal Models of Levodopa-Induced Dyskinesia. Mov Disord 28(8):1088-96 (2013). [cited by applicant]
Co-pending U.S. Appl. No. 19/025,296, inventor Bordbar; Aarash, filed Jan. 16, 2025. [cited by applicant]
Ko, Wai Kin D. et al. Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. Mov Disord… [cited by applicant]